{
}
UBS has lowered its price target for Cytokinetics (CYTK) from $47 to $41, maintaining a Neutral stance due to ongoing challenges. Despite this, analysts project an average target price of $77.30, indicating a potential upside of 111.51% from the current price of $36.55. The company reported significant revenue growth in Q4 2024, driven by partnerships, and holds $1.2 billion in cash, positioning it well for future initiatives.
Cytokinetics (CYTK) shares soared after Barclays issued an Overweight rating with a $55 price target, driven by expectations of FDA approval for aficamten. Analysts forecast an average target price of $78.68, indicating a potential upside of 95.25% from the current price of $40.30, with a consensus rating of 1.9 suggesting strong investor confidence. GuruFocus estimates a projected GF Value of $209.65, reflecting a potential upside of 420.22%.
Cytokinetics Inc
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs lowers price target for cytokinetics amid ongoing challenges
16:19 02.05.2025
Cytokinetics shares rise after Barclays issues bullish overweight rating
21:56 24.04.2025
Trending
Subcategory
Countries:
Companies:
Currencies:
People: